| Name | Title | Contact Details |
|---|
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
Why we`re excited: The mission for Payformance Solutions is simple. We aim to be a catalyst for payment transformation in the healthcare industry. Our proprietary software solutions allow payers and providers to focus on what really matters: providing patients with access to care that yields the best health outcomes, at the lowest costs. The healthcare industry is complex and fragmented. Payers and providers are faced with a lack of transparency and conflicting financial goals that fail to consider the health outcomes of patients. Payformance offers data-driven, turnkey software solutions that provide payers and providers with the technical tools and resources needed to design, evaluate, build, measure, and negotiate value-based reimbursement contracts — as a neutral third party. Our holistic solutions allow payers and providers to collaborate in an ecosystem that aligns financial goals with patient outcomes. Not to boast, but a little bit about us: Payformance Solutions is a health-tech company dedicated to advancing payment transformation in the healthcare industry. We are a wholly owned subsidiary of Altarum Institute, a nonprofit systems research and consulting organization that has been servicing government and private sector clients since 1946. Altarum Institute, as a non-profit, ensures that the public interest is always preeminent in client work. Our dedication to social responsibility is evident in all that we do, serving the public good with integrity and enabling others to do the same. Altarum develops and promotes best practices in the application of information technology to health and health care. Applying systems research principles and analytic objectivity, we work to increase access to health information; improve the organization and usability of health information; and develop new knowledge from health information.
Word and Brown is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Bolton Manor Nursing and Rehabilitation Center is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nutri-Mack is a Vineland, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.